The human tyrosyl transfer-RNA (tRNA) synthetase (TyrRS), which is well known for its essential aminoacylation function in protein synthesis, has been shown to translocate to the nucleus and protect against DNA damage caused by external stimuli. Small molecules that can fit into the active site pocket of TyrRS are thought to affect the nuclear role. The exploitation of TyrRS inhibitors has attracted attention recently. In this investigation, we adopted a structure-based virtual screening strategy and subsequent structure-activity relationship analysis to discover new TyrRS inhibitors, and identified a potent compound 5,7-dihydroxy-6,8-bis((3-hydroxyphenyl)thio)-2-phenyl-4H-chromen-4-one (compound 11, K i ¼ 8.8 mM). In intact HeLa cells, this compound showed a protective effect against DNA damage. Compound 11 is a good lead compound for the further development of drugs against disorders caused by DNA damage.
Introduction
Resveratrol (3,4,5-trihydroxystilbene, RSV), a natural product, is an important component of red wine. RSV has long been thought to impart benets in lifespan expectancy, 1,2 cancer chemopreventive activity, 3 cardioprotective, 4 and neuroprotective effects, 5 by launching a stress response. 6, 7 However, because it has low activity and the target of its action is not clear; 8 RSV is only marketed as a health care product. Human tRNA synthetase is a potent PARP1-activating effector target for RSV.
Recently, Sajish et al. demonstrated that RSV could interact with human tyrosyl transfer-RNA synthetase (TyrRS) and hence play its benecial role. 7 TyrRS was originally known for its essential aminoacylation function in protein synthesis. Recent studies have found a new function for TyrRS in DNA damage protection. 7, 9, 10 External stimuli, such as oxidative stress, can induce TyrRS to rapidly translocate from the cytosol to the nucleus. The nuclear-localized TyrRS activates transcription factor E2F1 to upregulate the expression of DNA damage repair genes such as BRCA1 and RAD51. 9 In particular, RSV can also trigger the translocation of TyrRS to the nucleus by directly binding to the active site of TyrRS, leading to the activation of NAD + -dependent auto-poly-ADP ribosylation of poly(ADP ribose) polymerase 1 (PARP-1). PARP-1 is a major stress response and DNA repair factor that has a considerable impact on longevity. 11 PARP-1 activated by TyrRS leads to activation of a series of protective genes, including the tumor suppressor gene p53, FOXO3A, or SIRT6. 7 Therefore, TyrRS is an attractive target for developing therapeutics for diseases of the nervous system diseases and for DNA damage protection.
To date, RSV is the only small molecule compound with an inhibition constant (K i ) value in the micromolar range that has been identied as an inhibitor of TyrRS. 7 However, RSV has also been identied as a modulator against many targets.
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Therefore, discovery of novel potent and selective TyrRS inhibitors, with scaffolds different from RSV, is desirable.
Here, we report the discovery of a new series of TyrRS inhibitors containing the scaffold 5,7-dihydroxy-2-phenyl-6,8-bis(phenylthio)-4H-chromen-4-one. These compounds were identied by a high throughput virtual screening and subsequent structure-activity relationship (SAR) analysis. The most active compound 5,7-dihydroxy-6,8-bis((3-hydroxyphenyl)thio)-2-phenyl-4H-chromen-4-one (11) was further investigated in binding mode analysis with TyrRS and bio-functional studies. 7, 9, 10, 16, 17 Compound 11 is a promising lead compound for the further development of drugs for DNA damage related diseases.
Results and discussion

Structure-based virtual screening of novel hit compounds against TyrRS
The virtual screening process is schematically shown in Fig. 1A . The chemical databases included the commercial chemical library Specs and an in-house database. In the rst step, compounds were ltered by Lipinski's rules and for pan-assay interference compounds (PAINS) in Pipeline Pilot 8.5, which is used for ltering pan-assay interference compounds 18, 19 and has been used with great success in drug discovery.
18,20 Then molecular docking was carried out with the remaining compounds. Here, the GOLD program was used because it provides good docking performance. 21 All the calculations were carried out on the platform of Accelrys Discovery Studio 3.1 (Accelrys Inc., San Diego, CA, USA). The crystal structure of TyrRS in complex with RSV (PDB entry 4Q93) was used for the docking studies, 7 and RSV was used as a reference molecule with a root-mean-square deviation (RMSD) of 0.57Å (Fig. S2 †) . Next, the consensus scoring strategy was used to score the compounds that may target TyrRS. Here, the scoring functions, GoldScore incorporated in the GOLD program and ID-Score developed by our laboratory, 22 were selected for the consensus scoring strategy because they have provide good performance for scoring. 18, 22 Finally, 30 compounds were selected from the top ranked compounds by the consensus scoring and visual inspection.
TyrRS enzyme inhibition assays
The 30 in silico-screened compounds were tested for inhibitory activity against TyrRS using the ATP-pyrophosphate exchange assay (Fig. 1B) . From the enzyme inhibition assay, the hit compounds AK-087/41343686, AH-357/03514064, and SKLB2002 were identied, they showed an enzyme activity < 60% against TyrRS at the concentration of 100 mM and inhibited TyrRS activity in biochemical assays in a dose-dependent manner with K i values of 187.9, 69.1, and 58.6 mM, respectively. The positive control compound RSV showed weak potency (K i ¼ 107.7 mM) ( Fig. 1C and S1 †) . Because the hit compounds AH-357/03514064 and SKLB2002 have similar scaffolds, and compound SKLB2002 was the most active compound and contained the new scaffold 5,7-dihydroxy-2-phenyl-4H-chromen-4-one, further structural optimization and SAR analysis were carried out on this compound.
Chemistry
All of the target compounds were prepared from the commercially available 5,7-dihydroxy-2-phenyl-4H-chromen-4-one. The general synthetic routes for compounds 1 (SKLB2002), 2-12, and 14-31 shown in Scheme 1. In route 1, intermediate 1a was prepared by a similar synthetic method as described in the literature.
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SAR analysis and optimization of hit compounds
The inhibitory effects of the synthesized compounds on human TyrRS are displayed in Tables 1 and 2 . As can be seen from Table  1 , the introduction of methyl, methoxyl, and tert-butyl groups, that is compounds 3, 6, 8, and 9, which substantially diminished activity. The series of derivatives (1, 2, 5, 7, 11, and 12) revealed that the presence of halogen or hydroxyl groups in the skeletal structure of these molecules was desirable; compound 7 and, in particular, compound 11, displayed an inhibition rate larger than 80% at a concentration of 100 mM. Compounds 7 and 11 strongly inhibited TyrRS with K i values of 10.6 and 8.8 mM, respectively, which were considerably higher than that shown by the positive control RSV (K i ¼ 107.7 mM, Fig. 2 and S1 †).
As can be seen from Table 2 , the R 2 and R 3 groups were also optimized. However, deletion of the benzenethiol-substituted unit at the 18-position of in the skeletal structure of these molecules was not ideal. Compounds 14-31 showed weaker potency compared with the benzenethiol-substituted compounds. Compound 11, K i ¼ 8.8 mM, was the most active compound and was the most promising inhibitor in the present series of derivatives.
Differential scanning uorimetry (DSF) and differential scanning calorimetry (DSC) assays
DSF is a good platform for screening protein stability conditions and has the advantages of being fast and inexpensive. Because of the small amount and low concentration of protein required, DSF can be used to identify low-molecular-weight ligands. A DSF assay was employed to understand the relationship between TyrRS inhibitor binding and protein construct stability 25, 26 ( Fig. 3A and B) . The impact of the binding of RSV and compound 11 on the TyrRS was explored by determining the changes in the melting temperature (T m ) of the protein in the absence and the presence of ligand. The shi in the T m as dened by the relative midpoint of the denaturation prole assay indicated that the thermal stability was dependent on the ligand concentration. As shown in Fig. 3A , the presence of compound 11 increased the T m value of the native TyrRS protein, showing that this class of inhibitor retained the ability to bind and stabilize the protein construct. Similarly, a signi-cant increase in the T m value was also observed for RSV, a specic binding ligand for this protein (Fig. 3B) .
DSC, a thermal analysis method, has become an efficient experimental technique for determination of the thermodynamic properties of biological macromolecules such as proteins.
27-29 A DSC assay was also performed to determine the T m values for TyrRS. In the DSC assay, the T m values of the TyrRS protein in the absence and presence of ligands were determined by the midpoint of the rise in each curve 30, 31 ( Fig. 3C and D) . The results obtained were comparable with the DSF method and showed the same trends. As shown in Fig. 3C and D, the presence of RSV or compound 11 shied the native TyrRS protein T m value by more than 1.84 or 1.30 C higher, respectively. a The pyridine ring was use to replace the benzenoid structure. Binding-mode analysis This observation prompted us to investigate whether compound 11 can regulate TyrRS nuclear localization in HeLa cells. By immunoblotting of the cytoplasmic and nuclear fractions from cells, we found that treatment with compound 11 dramatically promoted the nuclear localization of TyrRS in a concentration-dependent manner in HeLa cells, without the inuence of TyrRS in the cytoplasm (Fig. 5) .
Having demonstrated that nuclear localization of TyrRS is promoted by compound 11, we investigated the potential for TyrRS inhibitors to protect cells from DNA damage. We pretreated HeLa cells with compound 11 for 24 h before inducing DNA damage in cells by treatment with 30 mM cisplatin for 24 h. To visualize the DNA damage level in cells, phosphorylated histone H2A.X at S139 (g-H2A.X), used as a biomarker for DNA double-strand breaks, was detected by immunoblotting. Without cisplatin treatment, the level of g-H2A.X was below the detection limit (Fig. 6 ). However, with cisplatin treatment, g-H2A.X could be detected. We found that treatment with compound 11 dramatically decreased the level of g-H2A.X in HeLa cells, suggesting that nuclear TyrRS had a protective effect on DNA damage. Compound 7 had a similar effect as shown in Fig. S7 . †
Experimental
Ligand preparation
Compound libraries, including In-house and Specs databases, were used for virtual screening in this investigation. The total number of compounds is approximately 220 000. All the compounds were used for docking, which were prepared with 'Prepare Ligands' module in Discovery Studio (DS) 3.1 (Accelrys Inc., San Diego, CA, USA). Parameter values for "Change Ionization, Generate Tautomers, and Generate Isomers" were set to false. Other parameters were set to their default values. The compounds were retrieved according to previous reported.
18,34,35
Selected compounds were purchased in milligram quantities from chemical vendors or synthesis by our laboratory. Purity of compounds was $95%, as declared by the chemical vendors.
Structure-based virtual screening of novel hit compounds against TyrRS
In this investigation, the docking method GOLD was involved in the platform of DS 3.1. Before molecular docking, the receptor protein was prepared by the DS 3.1 soware package with standard preparation procedures (protein preparation protocol), which include removing water molecules, adding hydrogen atoms to the protein, and assigning force eld (here the CHARMm forceeld was adopted). For GOLD, the "predened generic algorithm (GA)" setting of 'automatic' was employed and others were set to default.
General procedure for the synthesis of compounds 1-31
All commercially available starting materials, solvents, and reagents were obtained from commercial suppliers and used without further purication unless otherwise indicated. Reactions were monitored by thin layer chromatography (TLC) on Merck silica gel 60 F-254 thin layer plates. 1 H NMR spectra was recorded on a Bruker AV-400 spectrometer at 400 MHz. Spin multiplicities are described as s (singlet), br. s (broad singlet), t (triplet), q (quartet), and m (multiplet). Chemical shis (d) are listed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. Mass spectral (MS) data were acquired on a Waters Q-TOF Premier mass spectrometer (Micromass, Manchester, U.K.). The 1 H NMR, 13 C NMR, and MS of compounds 1-31 are listed in the ESI. †
Purication of human TyrRS protein
Human TyrRS was puried as previously described. Hepes-Na, pH 7.5, 5 mM imidazole pH 7.5, 400 mM NaCl, 1Â PMSF, and 2 mM BME). Cells were lysed using a cell disrupter. Aer centrifugation at 14 000 rpm min À1 for 25 min at 4 C, the supernatant was loaded onto a nickel-affinity chromatography column (GE-Healthcare) pre-equilibrated with lysis buffer. The protein was eluted with a linear gradient of imidazole (0-300 mM). The desired fractions were pooled, concentrated and subjected to gel-ltration (Superdex 200; GE-Healthcare) chromatography and the protein peak corresponding to homogenous protein in buffer (20 mM Hepes-Na, pH 7.5, 50 mM NaCl, and 2 mM BME) was collected (see Fig. S3 †) . The quality of the protein purication was validated by SDS-PAGE analysis (see Fig. S4 †) .
In vitro enzymatic inhibition assays
In vitro enzymatic inhibition assays were performed using an ATP-pyrophosphate exchange assay as previously described 7 and the results provided by Reaction Biology Corp, Malvern, United States. Briey, tyrosyl adenylate synthesis was measured using the tyrosine-dependent ATP-pyrophosphate (PPi) exchange assay. A mixture containing 100 mM HEPES-Na (pH 7.5), 20 mM KCl, 2 mM ATP, 1 mM NaPPi, 2 mM DTT, 100 mM Ltyrosine (T3754-50G, Sigma), 0.02% Brij35 (w/v), 10 mM MgCl 2 , and approximately 0.01 mCi ml À1 Na[32P]PPi (NEX019001MC, PerkinElmer) was added to 12.5 nM puried TyrRS, pre- incubated with 0-300 mM of test compounds or 0-1000 mM of positive control RSV (ref. 7) at 4 C for 30 min. The ATP-PPi exchange reaction mixture was incubated at room temperature for 2 h, and aliquots were removed at specied time intervals and quenched in a mixture containing 40 mM NaPPi, 1.4% (w/v) HClO 4 , 0.4% (w/v) HCl, and 8% (w/v) of activated charcoal. Aer thorough mixing, the charcoal was ltered and washed with a solution of 7% HClO 4 (w/v) and 200 mM NaPPi using Spin-X Centrifuge Filters (Corning) containing 0.45 mm pore-size cellulose acetate lters. Aer drying, the charcoal was punched into scintillation vials and the radioactivity of the ATP bound to the charcoal mixture was measured by scintillation counting. The results of the L-tyrosine K m values and enzyme titration can be found in Fig. S5 and S6. † The K i value was calculated by the equation
Differential scanning calorimetry (DSC) assay
Human TyrRS (1 mg mL À1 ) was diluted in buffer (20 mM HepesNa, pH 7.4, and 400 mM NaCl) and melted using a Microcal VP Capillary DSC (GE Healthcare Life Sciences). Data were collected at 20-110 C, with a 200 C h À1 scan rate and 10 s ltering period. Data were analyzed in origin soware. TyrRS was incubated with 200 mM RSV or compound 11 for at least 0.5 h before melting.
Differential scanning uorimetry (DSF) assay
DSF experiments were performed on a RT-PCR detection system (BIO-RAD CFX96) according to the known protocol. 25 SYPRO orange (5000Â, Invitrogen) was monitored using the lters of FRET at the wavelength of 492 nm for excitation and of ROX at the wavelength of 610 nm for emission. Each reaction solution containing 2 mM protein in buffer (20 mM Hepes-Na, pH 7.4, and 100 mM NaCl), 5 Â SYPRO orange, and compound (10 mL) was heated from 25 to 95 C. Fluorescence intensities were recorded every 1 C min À1 and plotted as a function of temperature. The inection point of the transition curve (T m ) was calculated by tting the Boltzmann equation to the sigmoidal curve in GraphPad Prism 5.0. Each condition was tested in triplicate.
Cell cultures
HeLa cells were maintained in Dulbecco's modied Eagle's medium which was supplemented with 10% (v/v) fetal bovine serum. To mimic oxidative stress in cells, serum starvation under which condition cells were cultured in serum-free media was used. Cells were grown at 37 C and 5% CO 2 in a humidied incubator.
Detection of DNA damage in cells
To determine the protection of TyrRS inhibitors against DNA damage, HeLa cells pre-seeded in 6-well plate were pre-treated with compound 7 (30, 10, 3. Then whole cell lysates were extracted with radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime Biotechnology) that contained phenylmethanesulfonyl uoride (PMSF, Sigma) and protease inhibitor cocktail (Sigma) and subjected to immunoblot assays. Anti-Histone H2A.XS139ph (phospho Ser139) antibodies (GeneTex, GTX127340, 1 : 1000 dilution) were used to detect DNA damage levels in cells. Anti-bactin antibodies (Proteintech, 60008-1-Ig, 1 : 1000 dilution) were used to probe b-actin as a control.
Cellular localization of TyrRS
HeLa cells were treated with compound 7 (30, 10, 3.3, and 1.1 mM), compound 11 (30, 10, 3.3, and 1.1 mM), RSV (1 mM), or DMSO for 8 h. Cells cultured in serum-free media for 8 h were under serum starvation. The cytoplasmic and nuclear fractions were separated by NE-PER® nuclear and cytoplasmic extraction reagents (Thermo Scientic, 78835) as per the manufacturer's instructions. Both fractions were then subjected to immunoblot assays. Anti-tyrosyl tRNA synthetase antibodies (Abcam, ab150429, 1 : 1000 dilution) were used to probe TyrRS in the nucleus and cytoplasm. Anti-GAPDH antibodies (Proteintech, 60004-1-Ig, 1 : 1000 dilution) and anti-Lamin B1 (Proteintech, 1298.7-1-AP, 1 : 1000 dilution) antibodies were used to probe GAPDH and Lamin B1 as controls for the cytoplasmic and nuclear fractions, respectively.
Immunoblot assays
Proteins from cells were resolved by 12% or 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene uoride (PVDF) membranes (Millipore). The membranes were blocked with TBS-T blocking buffer (5% nonfat milk in TBS-T) for 1-4 h at RT and then probed with primary antibodies overnight at 4 C with gentle shaking. Aer three washes with TBS-T, the membranes were incubated with horseradish peroxidase-conjugated goat antimouse or anti-rabbit antibody (Proteintech, 1 : 5000 dilution) for 1 h at 37 C with gentle shaking. Aer extensive washing with TBS-T, the membranes were preserved in TBS, and the immunoblots were visualized by ECL (Abbkine). Immunoblots were quantied using Adobe photoshop soware.
Conclusions
A structure-based docking strategy was adopted to screen for novel TyrRS inhibitors. Aer two campaigns including virtual screening and bioassays, hit compounds with the novel scaffold 5,7-dihydroxy-2-phenyl-4H-chromen-4-one were selected for structural optimization and SAR analysis. The most active compound against TyrRS was compound 11 with a K i value of 8.8 mM. The results of orthogonal assays, including DSC and DSF assays, revealed that these compounds bind to the active site of TyrRS. Furthermore, compound 11 could protect against the DNA damage caused by cisplatin in intact HeLa cells. Therefore, these compounds represent useful probes for further research into the biological function of TyrRS.
